

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**

北京同仁堂國藥有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3613)**

**APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) is pleased to announce that Ms. Feng Li (“**Ms. Feng**”) has been appointed as an executive Director (“**Executive Director**”) of the Company with effect from 12 August 2022.

The biographical details of Ms. Feng are set out as follows:

**Feng Li**, aged 47, currently serves as the deputy general manager and the secretary to the board of directors of Beijing Tong Ren Tang Company Limited, the controlling shareholder (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) of the Company. Ms. Feng joined Beijing Tong Ren Tang Group in March 2012 and was formerly served as the manager of the Internal Audit and Legal Department, the assistant to the general manager and the manager of the Economic Operation Department of the Company. Prior to joining Beijing Tong Ren Tang Group, Ms. Feng worked as a senior audit manager at PricewaterhouseCoopers Zhongtian LLP. Ms. Feng graduated from the Department of International Economics of Peking University in 1998 with a bachelor's degree in economics and she is also a certified public accountant in China (non-practicing).

Ms. Feng shall hold office until the next following general meeting of the Company and if re-elected by the shareholders of the Company (the “**Shareholders**”) thereat, will be subject to retirement by rotation and re-election at annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. A service agreement (the “**Agreement**”) was entered into between the Company and Ms. Feng since 12 August 2022 for a period of three years. Pursuant to the Agreement, Ms. Feng will not receive any director’s fee as an Executive Director.

As at the date of this announcement, Ms. Feng does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

As at the date of this announcement, Ms. Feng has not held any directorship in any Hong Kong or overseas listed companies in the last three years. Save as disclosed above, Ms. Feng does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Listing Rules) of the Company nor does she hold any other position with the Company or any of its subsidiaries.

Save as disclosed above, Ms. Feng has confirmed that there is no other information relating to her that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the Shareholders in connection with the aforesaid appointment.

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Ding Yong Ling**  
*Chairman*

Hong Kong, 12 August 2022

As at the date of this announcement, the composition of the Board is as follows:

***Executive Directors:***

Ms. Ding Yong Ling (*Chairman*)  
Mr. Chen Fei  
Ms. Lin Man  
Ms. Feng Li

***Independent Non-executive Directors:***

Mr. Tsang Yok Sing, Jasper  
Mr. Zhao Zhong Zhen  
Mr. Chan Ngai Chi